4SC AG (FRA: VSC)
4.860
0.00 (0.00%)
At close: Sep 10, 2024
4SC AG Company Description
4SC AG, a biopharmaceutical company, engages in developing small-molecule drugs that address cancer diseases with high unmet medical needs in Germany.
Its product Resminostat, an orally administered histone deacetylase inhibitor for the treatment of cutaneous T-cell lymphoma, which is in clinical development stage.
The company also out-licenses its products to pharma and biotech companies. The company was founded in 1997 and is headquartered in Planegg, Germany.
4SC AG
Country | Germany |
Founded | 1997 |
Industry | Biological Products, Except Diagnostic Substances |
Employees | 13 |
CEO | Jason Loveridge |
Contact Details
Address: Fraunhoferstraße 22 Planegg, 82152 Germany | |
Phone | 49 89 700 763 0 |
Website | 4sc.com |
Stock Details
Ticker Symbol | VSC |
Exchange | Frankfurt Stock Exchange |
Fiscal Year | January - December |
Reporting Currency | EUR |
SIC Code | 2836 |
Key Executives
Name | Position |
---|---|
Jason Loveridge | Chief Executive Officer |
Kathleen Masch-Wiest | Chief Operating Officer |
Anna Niedl | Head of Investor Relations |